REFERENCES
1. Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et
al. Global, regional, and national deaths, prevalence,
disability-adjusted life years, and years lived with disability for
chronic obstructive pulmonary disease and asthma, 1990–2015: a
systematic analysis for the Global Burden of Disease Study 2015. Lancet
Respir Med. 2017 Sep;5(9):691–706.
2. Bahadori K, Doyle-Waters MM, Marra C, Lynd L, Alasaly K, Swiston J,
et al. Economic burden of asthma: a systematic review. BMC Pulm Med.
2009;9(1):24.
3. Flórez-Tanus Á, Parra D, Zakzuk J, Caraballo L, Alvis-Guzmán N.
Health care costs and resource utilization for different asthma severity
stages in Colombia: a claims data analysis. World Allergy Organ J
[Internet]. 2018 [cited 2018 Dec 1];11(1):26. Available from:
https://waojournal.biomedcentral.com/articles/10.1186/s40413-018-0205-4
4. Rodríguez-Martínez CE, Sossa-Briceño MP, Castro-Rodriguez JA.
Cost-utility analysis of the inhaled steroids available in a developing
country for the management of pediatric patients with persistent asthma.
J Asthma. 2013;50(4):410–8.
5. Erick Bateman. Global Strategy for Asthma Management and Prevention.
Glob Iniciative Asthma [Internet]. 2016 [cited 2019 Oct
22];1–147. Available from: www.ginasthma.org
6. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy:
Multiple suppressor factors at work in immune tolerance to allergens. J
Allergy Clin Immunol. 2014 Mar;133(3):621–31.
7. Reinhold T, Ostermann J, Thum-Oltmer S, Brüggenjürgen B. Influence of
subcutaneous specific immunotherapy on drug costs in children
sufferingfrom allergic asthma. Clin Transl Allergy. 2013 Dec 3;3(1):30.
8. Sánchez J, Sánchez A, Cardona R. Consecuencias económicas en la vida
real de la inmunoterapia con alérgenos en asma, rinitis y dermatitis.
Rev Alerg México. 2016;63(4):323.
9. Demoly P, Makatsori M, Casale TB, Calderon MA. The Potential Role of
Allergen Immunotherapy in Stepping Down Asthma Treatment. J Allergy Clin
Immunol Pract. 2017 May;5(3):640–8.
10. Asaria M, Dhami S, van Ree R, Gerth van Wijk R, Muraro A, Roberts G,
et al. Health economic analysis of allergen immunotherapy for the
management of allergic rhinitis, asthma, food allergy and venom allergy:
A systematic overview. Allergy. 2018 Feb;73(2):269–83.
11. Simoens S. The cost-effectiveness of immunotherapy for respiratory
allergy: a review. Allergy. 2012 Sep 1;67(9):1087–105.
12. Ehteshami-Afshar S, Zafari Z, Hamidi N, FitzGerald JM, Lynd L,
Sadatsafavi M. A Systematic Review of Decision-Analytic Models for
Evaluating Cost-Effectiveness of Asthma Interventions. Value Heal. 2019
Sep;22(9):1070–82.
13. Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S,
Alvarez-Puebla MJ. Three years of specific immunotherapy may be
sufficient in house dust mite respiratory allergy. J Allergy Clin
Immunol. 2011 Jan;127(1):57-63.e3.
14. Instituto de Evaluación Tecnológica en Salud-IETS. Manual para la
elaboración de evaluaciones económicas en salud [Internet].
Instituto de Evaluación Tecnológica en Salud. Bogotá - Colombia; 2014.
Available from:
https://www.iets.org.co/Archivos/64/Manual_evaluacion_economica.pdf
15. Bacharier LB. “Step-down” therapy for asthma: Why, when, and how?
J Allergy Clin Immunol. 2002 Jun;109(6):916–9.
16. Akinbami LJ, Sullivan SD, Campbell JD, Grundmeier RW, Hartert T V,
Lee TA, et al. Asthma outcomes: Healthcare utilization and costs. J
Allergy Clin Immunol. 2012 Mar;129(3):S49–64.
17. Kim CH, Dilokthornsakul P, Campbell JD, van Boven JFM. Asthma
Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in
Estimating Value? J Allergy Clin Immunol Pract. 2018 Mar;6(2):619–32.
18. Global Initiative for Asthma. Global Strategy for Asthma Management
and Prevention (Update 2019) [Internet]. 2019. p. 1–162. Available
from: www.ginasthma.org
19. Agache I, Lau S, Akdis CA, Smolinska S, Bonini M, Cavkaytar O, et
al. EAACI Guidelines on Allergen Immunotherapy: House dust mite‐driven
allergic asthma. Allergy. 2019 May 16;74(5):855–73.
20. Departamento Administrativo Nacional de Estadística (DANE). Vital
statistics: birth and deaths forecasting. 2018.
21. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for
asthma. Cochrane Database Syst Rev. 2010 Aug 4;(8).
22. Dhami S, Kakourou A, Asamoah F, Agache I, Lau S, Jutel M, et al.
Allergen immunotherapy for allergic asthma: A systematic review and
meta-analysis. Allergy Eur J Allergy Clin Immunol. 2017;72(12):1825–48.
23. Sánchez J, Cardona R, Sánchez A. Repercusión de la inmunoterapia con
alergenos luego de dos años de suspensión a pacientes con asma. Rev
Alerg México. 2016 May 11;63(2):113.
24. Romano G, Y A, López-Delgado N. Análisis de impacto presupuestal de
beclometasona, budesonida, ciclesonida, deflazacort, fluticasona
(propionato), formoterol, formoterol + budesonida, ipratropio bromuro,
metilprednisolona, mometasona, montelukast, omalizumab, prednisolona,
salbutamol y. Bogotá, Colombia; 2017.
25. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with
allergen-specific immunotherapy in children with asthma: A randomized
controlled trial. J Allergy Clin Immunol. 2010;126(5):942–9.
26. Lasserson TJ, Cates CJ, Lasserson EH, White J. Fluticasone versus
“extrafine” HFA-beclomethasone dipropionate for chronic asthma in
adults and children. Cochrane Database Syst Rev. 2006 Apr 19;(2).
27. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health
economic evaluation. Oxford University Press; 2006. 237 p.
28. Dennis R, Caraballo L, Garcia E, Rojas MX, Rondon MA, Perez A et al.
Prevalence of asthma and other allergic conditions in Colombia
2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17.
29. El-Qutob D, Moreno F, Subtil-Rodriguez A. Specific immunotherapy for
rhinitis and asthma with a subcutaneous hypoallergenic high-dose house
dust mite extract: Results of a 9-month therapy. Immunotherapy.
2016;8(8):867–76.
30. Brożek JL, Bousquet J, Agache I, Agarwal A, Bachert C,
Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma
(ARIA) guidelines—2016 revision. J Allergy Clin Immunol.
2017;140(4):950–8.
31. Ministerio de Salud y Protección social - Colciencias. Guía de
práctica clínica Para el diagnóstico, atención integral y seguimiento de
niños y niñas con diagnóstico de Asma. Bogotá - Colombia; 2013. 242 p.
32. Sanchez J. Clinical differences between children with asthma and
rhinitis in rural and urban areas. Colomb Med. 2018 Jun 1;49(2):169–74.
33. Ministerio de Salud y Protección Social. SISMED - Sistema de
Información de Precios de Medicamentos [Internet]. 2019 [cited
2019 Nov 11]. Available from:
https://www.sispro.gov.co/central-prestadores-de-servicios/Pages/SISMED-Sistema-de-Informacion-de-Precios-de-Medicamentos.aspx
34. Ministerio de Salud y Protección Social. Acuerdo No. 256 de 2001 -
Manual de Tarifas de la Entidad Promotora de Salud del Seguro Social.
Bogotá - Colombia; 2001.
35. Szende A, Leidy NK, Ståhl E, Svensson K. Estimating health utilities
in patients with asthma and COPD: evidence on the performance of EQ-5D
and SF-6D. Qual Life Res. 2009 Mar 23;18(2):267–72.
36. Lloyd A, Price D, Brown R. The impact of asthma exacerbations on
health-related quality of life in moderate to severe asthma patients in
the UK. Prim Care Respir J. 2007 Feb 3;16(1):22–7.
37. Stelmach I, Sobocińska A, Majak P, Smejda K, Jerzyńska J, Stelmach
W. Comparison of the long-term efficacy of 3- and 5-year house dust mite
allergen immunotherapy. Ann Allergy, Asthma Immunol. 2012;109(4):274–8.
38. Garrison LP. Cost-Effectiveness and Clinical Practice Guidelines:
Have We Reached a Tipping Point?—An Overview. Value Heal. 2016
Jul;19(5):512–5.
39. Jutel M, Brüggenjürgen B, Richter H, Vogelberg C. Real‐world
evidence of subcutaneous allergoid immunotherapy in house dust
mite‐induced allergic rhinitis and asthma. Allergy. 2020 Mar
12;(January):all.14240.
40. Schmitt J, Wüstenberg E, Küster D, Mücke V, Serup‐Hansen N, Tesch F.
The moderating role of allergy immunotherapy in asthma progression:
Results of a population‐based cohort study. Allergy [Internet]. 2020
Mar 8 [cited 2020 May 22];75(3):596–602. Available from:
https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14020
41. Brüggenjürgen B, Reinhold T, Brehler R, Laake E, Wiese G, Machate U,
et al. Cost-effectiveness of specific subcutaneous immunotherapy in
patients with allergic rhinitis and allergic asthma. Ann Allergy, Asthma
Immunol. 2008;101(3):316–24.
42. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al.
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good
Research Practices Task Force-3. Value Heal. 2012 Sep;15(6):812–20.
43. Dennis RJ, Caraballo L, García E, Rojas MX, Rondon M a, Pérez A, et
al. Prevalence of asthma and other allergic conditions in Colombia
2009–2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17.
44. Zakzuk J, Parra D, Salcedo Mejía F, Alvis-Zakzuk J, Buendia E,
Caraballo L, et al. Out-Of-Pocket Health Expenditures In Patients With
Uncontrolled Asthma From Colombia. Value Heal. 2016 May;19(3):A16.